Introduction: End-stage kidney disease (ESKD) in children is associated with multifactorial growth failure. Control of patients' parathyroid hormone level (PTH) may improve their growth.
Aim of the study: The study aimed to assess the relationship between PTH and IGF-1 levels in the blood and the impact of Cinacalcet on IGF-1 levels in children with ESKD on regular hemodialysis.
Methods: Thirty-five children with ESKD, aged eight to eighteen, on regular hemodialysis with uncontrolled hyperparathyroidism (HPT), were included in this prospective analysis. Cinacalcet was given to every child for three months. Blood IGF-1, parathyroid hormone (PTH), serum calcium, phosphorus, and alkaline phosphatase (ALP) were measured before and after three months following the administration of Cinacalcet.
Results: Serum IGF-1 levels were increased by 37.01 (± 22.07) % after cinacalcet therapy. Cinacalcet effectively lowered PTH levels by 58.3 (± 17.65) %. The mean value (± SD) of the percentage of change in Ca²⁺, phosphorus, and ALP were -2.3 (± 1.78) %, -8.1 (± 12.27) %, and 72 (± 5.24) %, respectively, which was a statistically significant change. Serum IGF-1 and serum PTH (r=-0.465 and P= 0.001), Ca2+ (r= -0.399 and P= 0.001), and serum phosphorus (r= -0.342 and P= 0.003) all showed a significant negative correlation.
Conclusions: For children with ESKD, cinacalcet controls sHPT and increases blood IGF-1 levels.